whereas in the majority of cases, a diet would settle the question
Bis ... a little extremist ...
And why not a bloodletting while we are there?
whereas in the majority of cases, a diet would settle the question
Quote:
whereas in the majority of cases, a diet would settle the question
Bis ... a little extremist ...
It reminds of Molière in the popular imagination. However, it did respond to certain biological situations, some of which still exist in blood samples (which is a recycled bloodletting) ... and doping!And why not a bloodletting while we are there?
The risks of Varenicline (Champix) reported by drug agencies are increasing and becoming more and more serious. They do not only concern the consumers of this drug but also the safety of the public.
The prescription of Varenicline (Champix) is strongly discouraged by an independent American institute which analyzed in 13 pages the FDA reports on the side effects of Champix. This product should be avoided:
1. By all people who have a psychiatric history or whose activities involve risks for the public in particular: drivers (train, coach, automobile) airplane pilots, crane operators.
2. By professionals who carry out control activities (dispatchers, air traffic controllers, employees of nuclear power plants, etc.).
3.All those who use work tools which can cause accidents when their operation is poorly controlled.
The American agency Federal Aviation Administration prohibited on May 18 the use of this drug to pilots and air traffic controllers who all were warned of the risks related to this drug in the exercise of their profession.
The patients had already been informed by the FDA that the perception by the patient or his entourage of the following symptoms: restlessness, mood change (anxiety depression), unusual behavioral changes, strange dreams, suicidal thoughts during or after cessation of treatment promptly required medical advice.
In addition to these undesirable effects already known and for which precautions for use have been provided by the manufacturer (Pfizer), other effects have appeared in recent months: road traffic accidents, falls responsible for fractures, loss of consciousness, muscle spasms, mental confusion, dizziness, vision disturbances heart rhythm disturbances seizures, skin reactions, diabetes.
In total, varenicline is the drug that caused the most reports of side effects to the FDA during the fourth quarter of 2007 (988 compared to interferon beta 640).
78 deaths have been reported in the USA in which varenicline was suspected
All of these side effects are probably not entirely attributable directly to varenicline and the publicity effect of the warnings previously issued by the FDA may have facilitated the reporting of adverse effects.
Varenicline obtained a European Marketing Authorization in 2006. This drug is derived from a vegetable alkaloid: cystisine which has partial agonist activity at the level of certain nicotinic receptors where its binding produces a sufficient effect to relieve the symptoms of craving and craving. (agonist activity), while simultaneously reducing the reward and strengthening effects of smoking by preventing the binding of nicotine to receptors (antagonist activity).
The clinical effects of this drug have been the subject of multiple studies. Modest efficacy after 12 weeks of treatment has been demonstrated [1] at one year against placebo and bupropion, but until recently Varenicline has not been compared to nicotine patches. A recent randomized but not blinded work partially filled this gap and showed a greater effectiveness of Varenicline after 12 weeks but without convincing due to the rapid fall in the rate of abstinence after 12 weeks.
Varenicline is the most expensive substitute in the treatment of smoking. The turnover of this drug consumed by 6.5 million people worldwide reached 883 million dollars in 2007. In France between February 2007 and November 2007 330000 smokers bought Champix (a 12-week course costs around 500 € )
Conclusion Varenicline is effective but really not more than products containing nicotine. Monitoring of this product has shown that the risks of its use are high. This medication exposes not only consumers but in certain professions (coach drivers, airplane pilots, crane operators) or when driving a car, the public. Given this information, it seems legitimate to advise against its prescription.
Notes
[1] Drug and Therapeutics Bulletin 2008; 46: 33-36
bidouille23 wrote:personally I am looking for the tree or shrub at the origin have made a copy in the form of medicine which one to call champix ...
Google, Varenicline tree wrote :Varenicline is a substance derived from a natural substance, cytisine, itself derived from a tree present in our countries, the cytisine.
"Cytisine could be helpful in quitting smoking
WASHINGTON, September 29, 2011 (APM) - Cytisin, extracted from the seeds of the cytisus (Cytisus laborinum), an ornamental tree, has been shown to be superior to a placebo in the treatment of smoking cessation, according to results published Thursday in the New England Journal of Medicine (NEJM).
Cytisine has been available in the former communist countries for more than 40 years as an aid to stop smoking, in particular under the brand Tabex * (Sopharma AD), recall Robert West of the University College of London and his colleagues.
Some of these countries have withdrawn the product from the market after their accession to the European Union, but it remains marketed in Poland with a processing cost of around 15 dollars, and in Russia where it is freely available for only 6 dollars.
The development of cytisine is unusual and despite studies strongly suggesting its effectiveness in smoking cessation, no randomized, placebo-controlled study corresponding to modern criteria of regulatory agencies has been conducted to date.
The researchers therefore evaluated cytisine against placebo in a single-center study of 740 adults who smoked an average of 23 cigarettes per day for 28 years.
The treatment lasted 25 days, each group also receiving smoking cessation counseling.
Cytisine treatment consisted of six doses of 1,5 mg tablets per day for three days, then five doses per day for nine days, four tablets per day for four days, three tablets per day for four days and finally two per day for the last five days.
Abstinence was assessed by measuring carbon monoxide in the exhaled air.
The sustained abstinence rate, that is to say throughout the year after stopping treatment, was 8,4% in patients who received cytisine, statistically more than in the placebo group (2,4 , XNUMX%).
At one year of follow-up, the prevalence of abstinence over one week was 13,2% among patients who received cytisine and 7,3% in the placebo group, a statistically significant difference.
The only side effects significantly more frequently reported with cytisine than placebo were gastrointestinal disturbances (13,8% vs. 8,1%).
According to the latest European drug safety report, no pharmacovigilance signal has been identified among the approximately 7 million people exposed to this drug.
These results confirm that cytisine can help quit smoking, the researchers conclude.
Additional studies are necessary to assess the effectiveness of a longer treatment as well as with the combination with behavioral support.
As the treatment for smoking cessation varenicline (Champix *, Pfizer) a partial agonist of alpha-4 beta-2 nicotinic receptors, cytisine could also act by reducing the withdrawal syndrome and the pleasure brought by a cigarette in the event of relapse, they comment.
With an abstinence rate comparable to other pharmacotherapies available for tobacco dependence (nicotine replacement therapy, Champix * as well as bupropion, Zyban * / GlaxoSmithKline) but at a reduced cost, cytisine appears to be an interesting therapeutic option, in particular in low to moderate income countries, they add. "
Back to "Science and Technology"
Users browsing this forum : No registered users and 135 guests